Clinical trials and observational studies indicate that EPO biosimilars can achieve comparable hemoglobin (Hb) targets to the reference EPO products in patients with anemia linked to CKD or induced chemotherapy. The gene discussed is GSTM1; the disease is anemia (phenotype).